|
H. Lundbeck A/S - Comparative Business Analysis Snapshot
Business Description
H. Lundbeck A/S. The Group's principal activities are the research, development, production, marketing and sale of pharmaceuticals for treating diseases of the central nervous system (CNS). The Group specialises in psychiatry and neurology, focusing exclusively on treatments of psychosis, depression, anxiety, schizophrenia, Parkinson's disease, Alzheimer's disease and dementia. The product group includes Cipralex, Lexapro, Azilect and other pharmaceuticals. The Group operates globally. The Group acquired Ovation Pharmaceuticals,Inc., USA on 9 Feb 2009
Competitor Analysis
This analysis compares H. Lundbeck A/S with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
